Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "|Years of enrollment" to "|Dates of enrollment")
m (Text replacement - "2 PubMed]" to "2/ PubMed]")
Line 36: Line 36:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312 PubMed] NCT02091141
+
# '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312/ PubMed] NCT02091141
 
[[Category:EGFR regimens]]
 
[[Category:EGFR regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Malignant solid neoplasm]]
 
[[Category:Malignant solid neoplasm]]
 
[[Category:Site-agnostic regimens]]
 
[[Category:Site-agnostic regimens]]

Revision as of 14:31, 26 April 2023

Back to Top

1 regimens on this page
1 variants on this page


All lines of therapy

Erlotinib monotherapy

Regimen

Study Dates of enrollment Evidence
Hainsworth et al. 2018 (MyPathway) 2014-2016 Phase 2a, <20 pts in this arm

Biomarker eligibility criteria

  • Gene: EGFR
  • Alteration: nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
  • Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
  • Biomarker exclusions: EGFR exon 20 mutations

Targeted therapy

Continued indefinitely

References

  1. MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141
Retrieved from "https://hemonc.org/w/index.php?title=Malignant_solid_neoplasm,_EGFR-mutated&oldid=68584"